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London, United Kingdom; and Pittsburgh, PennsylvaniaMulticellular organisms are built of cells embedded in the
interstitium, the scaffolding of organs and tissues. In disease,
the ratio between cells and interstitium changes due to
interstitial expansion as a result of increased collagen (focal
and diffuse ﬁbrosis) or accumulation of exogenous material
such as amyloid. In most organs and diseases (e.g., liver
cirrhosis), diffuse ﬁbrosis plays a key role, and ﬁbrosis quan-
tiﬁcation guides therapy. In the heart, diffuse ﬁbrosis appears
histologically ubiquitous, but it remains clinically invisible,
and the gold standard test, invasive myocardial biopsy, has
signiﬁcant morbidity and sampling error. CardiovascularSee page 1280magnetic resonance measures focal ﬁbrosis (scar) by using late
gadolinium enhancement, but this method is unable to
quantify diffuse ﬁbrosis. T1 mapping, a new cardiovascular
magnetic resonance technique, can now noninvasively quan-
tify the myocardial extracellular volume (ECV), reﬂecting
diffuse ﬁbrosis (1).
The longitudinal relaxation time (T1) of a tissue indicates
how rapidly protons recover after a radiofrequency pulse.
Pre-contrast (native) T1 varies with water content and may
increase in cases of diffuse myocardial ﬁbrosis (2), but it
inherently embodies composite signal from both cells and
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this paper.magnetic resonance imaging ﬁeld strength. After extracel-
lular gadolinium-based contrast administration, T1 is
dominated by and is inversely proportional to the concen-
tration of gadolinium. Measuring T1 after contrast provides
a value linked to the interstitium, but post-contrast T1 also
varies due to gadolinium dose, clearance rate, time post bolus,
body composition, and hematocrit. If the change in T1 pre-
contrast and post-contrast is measured in both blood and
myocardium after equilibration of the contrast distribution,
the partition coefﬁcient can be calculated. By correcting for
the hematocrit level, the myocardial ECV is derived, which is
a more stable and biologically signiﬁcant biomarker. The
utility of ECV measurement is increasingly being reported
across the spectrum of cardiology (3), and new data show
ECV, in unselected patients, predicts outcomes at least as
strongly as left ventricular ejection fraction (4,5).
In this issue of the Journal, Liu et al. (6) present a large
cohort, based on CMR data from 1,231 participants aged 54
to 93 years from the Multi-Ethnic Study of Atherosclerosis
(MESA) study, and investigated the relationship between
CMR indices and age/sex. The authors are congratulated
for integrating T1 measurement into the MESA study,
providing data on normal ranges, mechanisms of sex differ-
ences, and correlations with clinical ﬁndings from this well-
characterized cohort. Previously, only small, single-center
studies have demonstrated a correlation between ECV and
age (3). The authors used a single breath-hold Modiﬁed
Look-Locker Inversion recovery (MOLLI) (7) sequence in
one mid short axis slice, showing that women had signiﬁ-
cantly higher pre-contrast T1 times and partition coefﬁcient
as well as lower post-contrast T1 times than men. When
hematocrit data were available, ECV was higher in women
than in men (28.1  2.8% vs. 25.8  2.9%; p < 0.001).
Using multivariable linear regression, ECV increased with
age in men with every decade (p < 0.001), but in women,
ECV decreased with age. In the overall cohort, ECV was
correlated with age (R2 ¼ 0.021; p ¼ 0.012).
What are we to make of these results? At face value, they
may explain some sex differences in the prevalence of con-
gestive heart failure (8) and support the idea that diffuse
myocardial ﬁbrosis increases with age. However, unresolved
questions remain. Age and ECV correlated weakly, with an
R2 of only 0.021, meaning that 97.9% of all ECV variation
is explained by factors other than age. Although the age–
ECV relation was statistically signiﬁcant, the clinical sig-
niﬁcance is less certain. In fact, one could reasonably
conclude, that because age is so minimally related to
myocardial ﬁbrosis, most people can age successfully without
inexorable, age-related myocardial ﬁbrosisdan optimistic
interpretation indeed. Second, risk adjustment addressed the
presence of comorbidities but not their severity. Disease
severity, including longer “exposure” to comorbidity (e.g.,
hypertension), may increase with age and introduce residual
confounding not addressed by the statistical modeling.
Third, the sex-related results may be confounded by
menopause.
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1289From a technical perspective, the T1 mapping ﬁeld is
rapidly advancing. The iteration of the Modiﬁed Look-
Locker Inversion recovery (MOLLI) sequence used in this
study (6) has improved. Single breath-hold mapping (in
which each pixel carries the T1 value) has replaced multi
breath-hold methods, and newer reﬁnements include itera-
tive reconstruction, shorter breath-holds, better sequence
design, and, lately, ECV maps with pixel-by-pixel repre-
sentation of ECV for a simpliﬁed detection, measurement
and quantitative display of diffuse ﬁbrosis (9). There is an
apparent spectrum of interstitial expansion with cardiac
amyloid, aortic stenosis, and cardiomyopathy having large
changes in ECV; age and sex, however, have much smaller
or possibly no contributions (10). The ratio of pathophysi-
ological signal to measurement error determines test
performance. T1 mapping seems especially robust in
detecting disease characterized by high ECV, such as
amyloid (in which the ECV is often >0.5) (11) or marked
native T1 contrast diseases such as Anderson-Fabry disease
(in which fat storage makes native T1 fall) (12).
The ﬁeld of T1 mapping and noninvasive ﬁbrosis quan-
tiﬁcation faces the same challenges as any other new tech-
nology. A key task will be to let the energy and creative
chaos of early development and competing methodologies
(e.g., different scanner manufacturers, contrast agents, ﬁeld
strengths, T1 mapping sequences) transition through col-
laboration into more standardized methodologies sufﬁcient
for use to: diagnose disease; deﬁne mechanistic pathways of
disease affecting the interstitium, the myocyte, or both;
change therapy; and use ECV as a surrogate endpoint in
trials of drug development, an aim underpinning the recently
formed T1 mapping development group.
Ultimately, ECV diffuse ﬁbrosis measures could dra-
matically affect cardiology. We can now dichotomize the
myocardium into its cellular and interstitial components,
and advance understanding of disease mechanisms and their
relative contribution to cardiac vulnerability, which are
critically important issues. More data demonstrating ﬁbrosis
as a therapeutic target are needed, but because ﬁbrosis guides
research and patient management in liver and lung disease,
the same principles may apply to the heart. Conceivably, T1
mapping for ECV could facilitate drug development and
guide therapy, especially in the setting of heart failure, in
which drug development strategies have produced few
positive results over the last decade (13). Exciting times are
ahead. Cardiac ﬁbrosis promises to be as fundamental asﬁbrosis elsewhere. Its measurement may deﬁne disease,
predict outcome, determine the choice and timing of
interventions, enhance drug development, and be more
treatable.
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